Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 4301–4350 of 18410
In connection with the Reduction in Force, Scott B. Brown, CPA, Chief Financial Officer and Secretary will cease serving as an officer of the Company effective July 31, 2024.
On July 30, 2024, Charles P. Theuer, M.D., Ph.D., tendered his resignation as the Company’s President and Chief Executive Officer, to be effective as of July 31, 2024.
his intended successor, Edward Cooper Werner, the Company’s current Senior Vice President of Finance, who is slated to be appointed upon Mr. Pelzer’s retirement.
On July 26, 2024, Frank Pelzer, Executive Vice President and Chief Financial Officer of F5, Inc. (the “Company”), informed the Company of his plans to retire during the Company’s first fiscal quarter 2025, which ends December 31, 2024.
Christopher S. Sotos informed Clearway Energy, Inc. (“ Clearway, Inc. ”), the parent company of the Company, on April 30, 2024 that, effective as of June 30, 2024, he will move on from his position as President and Chief Executive Officer of Clearway, Inc. and the Company.
On July 30, 2024 Hudson Technologies, Inc. (the “Company”) appointed Brian J. Bertaux as its Vice President, Chief Financial Officer and Secretary.
Simultaneously, on such date, Nat Krishnamurti stepped down, effective immediately, from his positions as Vice President, Chief Financial Officer and Secretary of the Company.
Philip Bacchus, who will serve as SVP, Chief Financial Officer effective August 26, 2024, will participate in the Change in Control Plan at Tier 2
On July 25, 2024, the Board appointed Adam Wyll, the Company’s President and Chief Operating Officer, to fill the role of Chief Executive Officer at the Company effective January 1, 2025.
On July 24, 2024, the Board of Directors (the “Board”) of the Company approved the appointment of Kevin Strange as the Chief Financial Officer of the Company as of the Effective Date, succeeding Mr. Hill.
On July 24, 2024, Mitch Hill notified Inari Medical, Inc. (the “Company”) of his decision to retire as Chief Financial Officer of the Company, effective as of October 1, 2024 (the “Effective Date”).
(ii) Steven T. Gallagher, currently the Company’s Senior Vice President, Chief Accounting Officer, and interim Chief Financial Officer and Treasurer, to Executive Vice President, Chief Financial Officer and Treasurer,
Christopher Meinerz, the Company’s Chief Financial Officer, notified Kent Wilson, the Company’s Chief Executive Officer, and the Board of Directors (the “Board”) that Mr. Meinerz intends to resign as the Company’s Chief Financial Officer effective on or by August 30, 2024.
appointed Ginger Smith, currently serving as the Company’s Corporate Controller, to serve as interim Chief Financial Officer until the company hires a permanent replacement.
On July 26, 2024, the Board of Directors elected Benjamin J. Tisch as President and Chief Executive Officer of the Corporation, effective January 1, 2025.
The Board appointed Kendra Bracken-Ferguson as Chief Executive Officer of the Company effective as of July 30, 2024.
Dr. Vignola’s continued service as Chief Financial Officer for a transition period until the date of his separation from employment (the “Vignola Separation Date”), anticipated to be February 1, 2025.
The Board terminated Mr. Matosevic as President, Chief Executive Officer and Board member without severance for cause, per his employment agreement.
As previously disclosed, on June 3, 2024, Amarin Corporation plc (the “Company”) announced that Aaron Berg was appointed to the role of President and Chief Executive Officer (and principal executive officer) of the Company, effective June 4, 2024
the Board of Directors of the Company has appointed Tim Foote, age 44, to replace Mr. Rai as CFO with effect as of July 29, 2024.
Steve Rai, the Company’s Chief Financial Officer (“CFO”), intends to leave the Company to pursue other opportunities
The Champi Employment Agreement contemplates that Peoples and Peoples Bank will promote Mr. Champi to the position of Chief Executive Officer on or prior to July 1, 2025.
the Company’s board of directors (the “Board”) appointed Malte Peters, M.D., as the Company’s Chief Executive Officer and President, effective July 22, 2024.
On July 22, 2024, Reinhard Kandera separated as the Chief Financial Officer of the Company.
On July 22, 2024, Joern Aldag separated as the Chief Executive Officer of HOOKIPA Pharma Inc. (the “Company”).
On July 22, 2024, Alexander Hornung resigned as Chief Financial Officer of Mountain & Co. I Acquisition Corp.
Brad Tade, former Vice President, Financial Operations of ADMA Biologics, Inc. (the "Company"), was promoted to Chief Financial Officer and Treasurer of the Company
Immediately after the Merger Effective Time, it is currently anticipated that Mr. Fabio Celadon, Executive Vice President of Strategy and Corporate Development for IGT, will be named Chief Financial Officer of Newco .
Effective as of Mrs. Sachdeva’s appointment, Bryan Hill, the Company’s Chief Financial Officer and principal financial officer, will no longer serve as the Company’s interim principal accounting officer.
Jamal (Jamie) Khurshid, the Chief Operating Officer and a director of the Company, was appointed as Chief Executive Officer effective July 24, 2024.
On July 24, 2024, Emil Assentato resigned as Chief Executive Officer and from the Board of Directors of Nukkleus Inc. (the “Company”), effective immediately.
Vanessa Kanu will succeed Mr. Kuhn as Executive Vice President, Chief Financial Officer of the Company, effective January 1, 2025.
On July 24, 2024, the Company entered into a letter agreement with Robert Volke (the “ Volke Agreement ”) providing for the termination of Mr. Volke’s employment as the Company’s Senior Vice President and Chief Financial Officer to pursue other opportunities, with the termination to be effective October 25, 2024
On July 19, 2024, Leone Patterson, Chief Financial and Business Officer (“CFBO”) of Tenaya Therapeutics, Inc. (“Tenaya” or the “Company”), advised Tenaya that she was resigning from her role as CFBO, Principal Financial Officer and Principal Accounting Officer to pursue another opportunity.
appointed Michael Verdeschi to succeed Peter B. Crawford as the Company’s Managing Director and Chief Financial Officer, effective as of October 1, 2024.
appointed Michael Verdeschi to succeed Peter B. Crawford as the Company’s Managing Director and Chief Financial Officer, effective as of October 1, 2024.
On July 19, 2024, the Board of Directors (the “Board”) of Zymeworks Inc. (the “Company”) appointed Ms. Leone Patterson, age 61, as Executive Vice President, Chief Business Officer and Chief Financial Officer of the Company, effective upon her commencement of employment with the Company, which is anticipated to be September 1, 2024
Jaime Martinez, Senior Vice President, Finance, Flex Reliability Solutions, will serve as the Company’s Interim Chief Financial Officer, effective August 1, 2024
On July 19, 2024, Mr. Paul R. Lundstrom, Chief Financial Officer of Flex, notified the Company that he is resigning to pursue another career opportunity, effective July 31, 2024.
On July 18, 2024, the board of directors of Versus Systems Inc. (the “Company”), appointed Geoff Deller as Chief Financial Officer, effective immediately, and approved an offer from the Company to Mr. Deller (the “Deller Offer Letter”).
the board of directors of Pubco appointed the following officers: Hok Wai Alex Ko as Chief Executive Officer and Chun Kit Tsui as Chief Financial Officer.
the board of directors of Pubco appointed the following officers: Hok Wai Alex Ko as Chief Executive Officer and Chun Kit Tsui as Chief Financial Officer.
The Company appointed a new Chief Financial Officer, Jennifer Calabrese, effective as of July 24, 2024, after serving as the Company’s outside consultant providing accounting and financial reporting services to the Company since September 2022.
As of the same date, Anna Apostolova stepped down as Chief Financial Officer to pursue other opportunities.
Mr. Hanson’s separation from the Company and resignation as a director became effective July 21, 2024, and his resignation is not the result of any disagreement with the Company.
appointed Carrie E. Cass as Chief Financial Officer of the Company, to be effective on August 5, 2024.
On July 17, 2024, the Company announced the appointment of Jeff Parsons as Chief Financial Officer of the Company and its wholly owned subsidiary, Zircon, following the retirement of Ron Bourque.
On July 19, 2024, Charles B. Lobetti, III, Chief Financial Officer (“CFO”) and principal accounting officer of Healthcare Integrated Technologies, Inc. (the “Company”) notified the Company of his decision to resign, effective as of July 31, 2024 (the “Effective Date”), in order to pursue other business opportunities.
On July 23, 2024, the board of directors of MSC Income Fund, Inc. (the “Company”) appointed Cory E. Gilbert to serve as the Company’s Chief Financial Officer and Treasurer, effective immediately.
On July 22, 2024, the Board of Directors of the Company approved the appointment of J. Scott Dixon as non-interim Chief Financial Officer, effective immediately.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.